Neos Therapeutics to Present at BMO Prescription for Success Healthcare Conference
December 07 2016 - 8:00AM
Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company
focused on developing and commercializing innovative
extended-release (XR) products for the treatment of
attention-deficit/hyperactivity disorder (ADHD), today announced
that Vipin Garg, Ph.D., president and chief executive officer, will
participate in a fireside chat at the upcoming BMO Prescription for
Success Healthcare Conference on Wednesday, December 14, 2016 at
9:00 a.m. ET in New York, NY.
A live webcast of the presentation will be available on the
Investor Relations page of the company’s website at
http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on
developing, manufacturing and commercializing products utilizing
its proprietary modified‐release drug delivery technology
platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in
patients 6 years of age and older, is the first approved product
using the Company’s XR-ODT technology platform. Neos, which is
initially focusing on the treatment of ADHD, has two other branded
product candidates that are XR medications in ODT or oral
suspension dosage forms. In addition, Neos manufactures and markets
its generic equivalent of the branded product Tussionex®1, an XR
oral suspension of hydrocodone and chlorpheniramine indicated for
the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of
Companies.
Contact:
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
Sarah McCabe
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Apr 2024 to May 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From May 2023 to May 2024